UNSPSC 51391610: Aminophylline dihydrate

This classification denotes the dihydrate form of a phosphodiesterase inhibitor and bronchodilator with the molecular formula 2C7H8N4O2.C2H8N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27Y3KJK423, chemically known as 3,7-dihydro-1,3-dimethyl-1h-purine-2,6-dione but more generally known as aminophylline, which bears US NIH Compound Identifier 2153. Aminophylline most often comes in base, anhydrous, and dihydrate forms.

UNSPSC 51391610 Aminophylline dihydrate is a Commodity code for a specific pharmaceutical product, but the recent state and local opportunities tagged to it show minimal alignment with aminophylline procurement itself. Instead, the code appears in solicitations for naloxone (an opioid antagonist) and pharmacy benefit management programs that address drug deactivation and direct-to-manufacturer prescription fulfillment — products and services substantially different from the narrow aminophylline product scope. State and local health departments and human services agencies issue these opportunities, which target pharmaceutical supply chain operations rather than a single active pharmaceutical ingredient.

The geographic footprint is limited to recent visible activity: Seminole County, Florida posted an IFB for naloxone and drug deactivation systems with a July 26, 2023 response deadline (solicitation IFB60459723LAS), and the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs (HHS0017013) with a April 3, 2026 response date. The code shows sparse and scattered recent activity, and the mismatch between the nominal aminophylline product and the actual procurement objects (naloxone, pharmacy benefit management) suggests this code may not reflect the true pharmaceutical categories under which state and local governments are actively buying.